BELARDINELLI LUIZ,GILLIES HUNTER CAMPBELL,LIANG FAQUAN,SHRYOCK JOHN,YANG SUYA
申请号：
NZ70721311
公开号：
NZ707213A
申请日:
2011.10.14
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
The disclosure relates to a combination therapy comprising a therapeutically effective amount of a selective type-A endothelin receptor antagonist (ERA) selected from the group consisting of ambrisentan, sitaxsentan and pharmaceutically acceptable salts thereof, and a therapeutically effective amount of a phosphodiesterase type 5 (PDE5) inhibitor selected from the group consisting of sildenafil, tadalafil, vardenafil and pharmaceutically acceptable salts thereof, wherein the weight ratio of the selective type-A ERA and the PDE5 inhibitor is in a range from about 1:1 to about 1:10. The disclosure also relates to the use of this combination for treating pulmonary hypertension.
